An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
Due to the COVID-19 pandemic, the global Vaccine Adjuvants market size is estimated to be worth US$ 852.8 million in 2021 and is forecast to a readjusted size of US$ 1569.9 million by 2028 with a CAGR of 9.0% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Vaccine Adjuvants market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Vaccine Adjuvants landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The top 5 global manufacturers of vaccine adjuvants are GSK, CSL Limited, Croda, SEPPIC, Novavax, which have a combined market share of about 55 percent. North America is the largest market, with a share about 38%, followed by Europe and Asia Pacific with the share about 27% and 22%.
This report focuses on Vaccine Adjuvants volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Vaccine Adjuvants market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe and China, etc.
Global Vaccine Adjuvants Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Aluminum Adjuvant
Emulsions Adjuvant
Others
Segment by Application
Human Vaccine
Veterinary Vaccine
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
GSK
CSL Limited
Croda
SEPPIC
Novavax
SPI Pharma
Phibro
SDA BIO
Invivogen
Tj Kaiwei
OZ Biosciences
Brenntag Biosector
MVP Laboratories
Zhuoyue
Aphios